30 May 2018 in The Journal of Physiology
4 October 2021 in British Journal of Pharmacology
Background and Purpose: The KCNQ2 gene encodes for the Kv7.2 subunit of non‐inactivating potassium channels. KCNQ2‐related diseases range from autosomal dominant neonatal self‐limited epilepsy, often caused by KCNQ2 haploinsufficiency, to severe encephalopathies caused by KCNQ2 missense variants. In vivo and in vitro effects of the sodium channel blocker eslicarbazepine acetate (ESL) and eslicarbazepine metabolite (S‐Lic) in a mouse model of self‐limited neonatal epilepsy as a first attempt to assess the utility of ESL in the KCNQ2 disease spectrum was investigated.Experimental Approach: Effects of S‐Lic on in vitro physiological and pathological hippocampal neuronal activity in slices from mice carrying a heterozygous deletion of Kcnq2 (Kcnq2+/−) and Kcnq2+/+ mice were investigated. ESL in vivo efficacy was investigated in the 6‐Hz psychomotor seizure model in both Kcnq2+/− and Kcnq2+/+ mice.Key Results: S‐Lic increased the amplitude and decreased the incidence of physiological sharp wave–ripples in a concentration‐dependent manner and slightly decreased gamma oscillations frequency. 4‐Aminopyridine‐evoked seizure‐like events were blocked at high S‐Lic concentrations and substantially reduced in incidence at lower concentrations. These results were not different in Kcnq2+/+ and Kcnq2+/− mice, although the EC50 estimation implicated higher efficacy in Kcnq2+/−animals. In vivo, Kcnq2+/− mice had a lower seizure threshold than Kcnq2+/+ mice. In both genotypes, ESL dose‐dependently displayed protection against seizures.Conclusions and Implications: S‐Lic slightly modulates hippocampal oscillations and blocks epileptic activity in vitro and in vivo. Our results suggest that the increased excitability in Kcnq2+/− mice is effectively targeted by S‐Lic high concentrations, presumably by blocking diverse sodium channel subtypes.
1 December 2017 in Neuroscience
1 August 2017 in Neuroscience Letters
18 May 2026 in Proceedings of the National Academy of Sciences
Autoantibodies against leucine-rich glioma inactivated 1 protein (LGI1) lead to limbic encephalitis, a rare neurological autoimmune disorder characterized by faciobrachial dystonic seizures and memory deficits. While animal models provide precious insights into the mechanisms of LGI1 autoantibody action, species-specific confirmation is lacking. In this study, we investigated the effects of patient-derived LGI1 monoclonal antibodies (LGI1 mAb) on CA3 pyramidal neurons using cultured ex vivo human hippocampal slices, providing a unique platform to study disease mechanisms in a homologous, clinically relevant context. Under incubation conditions, human CA3 neurons preserved their morphology, were intrinsically excitable and received spontaneous excitatory currents with large amplitudes and frequencies suggestive of “giant” AMPA receptor-mediated currents. In slices exposed to LGI1 mAb, human CA3 pyramidal neurons displayed increased action potential (AP) firing frequency, mirroring the effects observed with the K v 1.1 channel blocker dendrotoxin-K (DTX-K). This increase likely resulted from a decreased K v 1.1 channel activity at the axonal initial segment, as indicated by alterations in AP properties, including spike latency at rheobase and depolarizing ramp slope. Differences between LGI1 mAb and DTX-K effects on some AP properties suggested distinct mechanisms of action and emphasized the need for further exploration of downstream pathways. Our findings underscore the importance of species-specific confirmatory studies of disease mechanisms and give insight into possibilities and limitations of human hippocampal slice cultures as a translational model for the investigation of disease mechanisms beyond epilepsy, including the effects of pharmacological compounds and autoantibodies.
28 October 2024 in bioRxiv
Autoantibodies against leucine-rich glioma inactivated 1 protein (LGI1 mAb) lead to limbic encephalitis characterized by seizures and memory deficits. While animal models provide insights into mechanisms of LGI1 mAb action, species-specific confirmation is lacking. In this study, we investigated the effects of patient-derived LGI1 mAb on human CA3 neurons using cultured ex vivo slices. Analysis of intrinsic properties and morphology indicated functional integrity of these neurons under incubation conditions. Human CA3 neurons received spontaneous excitatory currents with large amplitudes and frequencies, suggestive of “giant” AMPA currents. In slices exposed to LGI1 mAb, human CA3 neurons displayed increased neuronal spike frequency, mirroring effects observed with the K v 1.1 channel blocker DTX-K. This increase likely resulted from decreased K v 1.1 channel activity at the axonal initial segment, as indicated by alterations in action potential properties. A detailed analysis revealed differences between LGI1 mAb and DTX-K effects on action potential properties, suggesting distinct mechanisms of action and emphasizing the need for further exploration of downstream pathways. Our findings underscore the importance of species-specific confirmatory studies of disease mechanisms and highlight the potential of human hippocampal slice cultures as a translational model for investigation of disease mechanisms beyond epilepsy, including the effects of pharmacological compounds and autoantibodies. Significance: This study advances our understanding of how autoantibodies against the LGI1 protein, known to cause limbic encephalitis, impact human neurons. By using cultured slices of human hippocampus derived from epilepsy’s surgical resections, we were able to observe the direct effects of these autoantibodies on neurons, specifically CA3 pyramidal cells. Our findings reveal that the autoantibodies increase neuronal activity, similar to what is seen with potassium channel blockers and in animal models. This work emphasizes the importance of studying living tissue from the human brain to confirm disease mechanisms, and demonstrates the potential of using human brain slices as a model for exploring not only epilepsy but also other neurological diseases and drug effects.